冠昊生物 (300238)

深圳
13.36
-0.09(-0.67%)
  • :
    1,346,385
  • 卖价/买价:
    13.36/13.37
  • 当日幅度:
    13.23 - 13.45
预计在7天内发布财报

300238历史数据

时间范围:
每日
2022/07/18 - 2022/08/18
13.3613.4413.4513.231.35M-0.67%
13.4513.3613.4913.321.50M+0.67%
13.3613.4113.4113.281.24M-0.07%
13.3713.3613.4313.241.25M-0.07%
13.3813.4613.4813.321.99M-0.15%
13.4013.1513.4313.102.59M+2.52%
13.0713.2013.2113.041.41M-0.98%
13.2013.3713.3713.141.50M-0.53%
13.2713.2513.3013.031.73M+0.91%
13.1512.9513.1712.942.01M+1.23%
12.9912.7913.0112.791.74M+1.80%
12.7612.6913.0512.692.32M-0.47%
12.8213.4113.4212.674.67M-5.25%
13.5313.4113.5513.352.06M+0.67%
13.4413.6813.7013.403.13M-1.68%
13.6713.7113.7713.653.00M+0.07%
13.6613.6813.8313.603.25M-0.44%
13.7213.6513.7813.513.19M+0.15%
13.7013.8413.9613.603.29M-0.65%
13.7914.2514.3313.694.96M-2.20%
14.1014.2514.3914.016.96M-2.96%
14.5314.7615.0814.2212.64M+1.96%
14.2513.6014.6313.507.70M+4.78%
13.6013.5513.6113.302.31M+1.87%
最高: 15.08最低: 12.67差价: 2.41平均: 13.48涨跌幅: 0.07
  • 冠昊生物在最新发布的《投资者关系活动记录表》中透露,根据《关于公布京津冀及黑吉辽蒙晋鲁医用耗材联合带量采购中选结果的通知》,公司有三款眼科产品中标。随着我国老龄化进程的加剧,白内障患者人数将呈现长期增长趋势,人工晶体市场还有很大的发展空间。 资料来源:资产信息网(小程序:资产信息)
    0